FDA Priority Review Voucher Program: Will Makary's Initiative Survive?

FDA Priority Review Voucher Program: Will Makary's Initiative Survive?

The FDA's National Priority Voucher program, championed by former Commissioner Makary, faces uncertainty amid congressional investigations and industry pushback. This analysis examines the program's survival prospects and impact on drug review timelines, voucher sales, and rare disease incentives.

Key Takeaways

• The FDA's Commissioner's National Priority Voucher pilot, offering one- to two-month review cycles, is under bipartisan congressional investigation and has drawn formal requests for a pause from drug companies and patient groups, as STAT reported.
• Uncertainty around the program threatens the secondary market value of existing priority review vouchers — including those tied to Casgevy — and could reshape the incentive structure for rare disease developers who have historically used voucher sales to fund early-stage pipeline work.
• BD teams and investors should track congressional hearings and FDA leadership signals closely; the outcome will directly affect companies such as RevMed and Hikma that may rely on accelerated pathways to compress time-to-market for high-priority indications.

Why is Makary's voucher program under investigation?

Roughly a year ago, then-FDA Commissioner Marty Makary launched the Commissioner's National Priority Voucher (CNPV) pilot program, promising to collapse standard drug review timelines — which typically run ten to twelve months — down to just one or two months for products that address agency-designated national priorities. The initial blueprint authorized five vouchers, each granting sponsors enhanced communications with reviewers and rolling review capabilities to facilitate the compressed schedule. Almost immediately, the program attracted scrutiny from multiple fronts. Two members of Congress — Rep. Frank Pallone Jr. and Rep. Cathy McMorris Rodgers — opened an investigation into Makary's use of the vouchers, citing concerns about safety, resource allocation, and public health impact. In a November 2025 letter to the FDA, the lawmakers demanded detailed records on how voucher recipients were selected, what safety data were reviewed, and whether the compressed timelines compromised the agency's ability to evaluate benefit-risk profiles for novel therapies. Drug companies and patient groups have also publicly urged the FDA to pause the program, arguing that one- to two-month reviews leave insufficient time for thorough safety assessments — particularly for products targeting rare or complex diseases where real-world evidence is limited at the time of filing. The congressional probe has placed the entire voucher ecosystem under a cloud of uncertainty, leaving industry participants to question whether the pilot will survive under new FDA leadership or be substantially restructured before it issues the remaining vouchers.

How will the uncertainty affect pharma BD teams and investors?

For business development teams and investors, the stakes are concrete and measurable. Companies that hold or have acquired priority review vouchers face potential devaluation if the CNPV program is paused, modified, or retired. One visible example is the voucher associated with Casgevy, the CRISPR-based therapy for sickle cell disease and beta-thalassemia. Although that voucher was issued under a different FDA mechanism, the secondary market for FDA priority review voucher sale transactions has historically treated all agency-issued vouchers as part of an interconnected ecosystem. Any disruption to the CNPV pilot could depress demand and pricing for voucher trades across the board, affecting the balance sheets of companies that have counted voucher proceeds in their financing plans. Conversely, if the program survives and expands beyond the initial five vouchers, it could dramatically accelerate time-to-market for therapies addressing urgent public health needs. Developers like RevMed and Hikma, both of which are pursuing high-priority indications in oncology and generics respectively, would benefit from faster review cycles that shorten the gap between regulatory submission and commercial launch. For investors, the key catalyst dates to watch are the upcoming congressional hearings, any testimony from current FDA leadership about the program's fate, and the agency's next public update on whether it will issue the remaining vouchers in the pilot. The scrutiny also underscores a strategic imperative for development teams: expedited reviews place a premium on pre-submission evidence quality. Companies that invest early in robust safety data packages and clear benefit-risk narratives will be best positioned to take advantage of accelerated pathways — whether under the CNPV or traditional priority review mechanisms.

What comes next for the FDA priority review voucher program?

The program's survival hinges on several unresolved questions. First, will the FDA under new leadership defend the CNPV pilot or distance itself from Makary's signature initiative? The agency has not committed to expanding the program beyond the initial five vouchers, and its website currently states that the pilot "will not affect other" existing review programs. Second, will the congressional investigation produce legislative action? The lawmakers' letter requested detailed accounting of how the vouchers were awarded and whether any conflicts of interest influenced the selection process. If the probe uncovers procedural lapses, Congress could move to defund or restrict the program through appropriations riders. Third, what signal will the market send? The FDA priority review voucher program has long been a tool for rare disease developers to monetize their regulatory successes. If the CNPV uncertainty leads to a sustained drop in voucher prices, it could reduce the incentive for companies to invest in therapies for small patient populations, particularly in gene therapy and precision medicine where development costs are high and commercial returns uncertain. For BD teams tracking the National Priority voucher program scrutiny, the next six months are critical. Any signal from the FDA — whether a pause, an expansion, or a set of new guardrails — will reset the valuation of outstanding vouchers and reshape the strategic calculus for companies deciding whether to pursue accelerated review pathways. The FDA's CNPV pilot page continues to describe the program as active, but the political and regulatory headwinds are building faster than the agency has acknowledged publicly.

Frequently Asked Questions

Related coverage

• FDA Voucher Program Under Fire: Pharma and Patient Groups Demand Pause
• STAT Supreme Court backs generic drugmaker in 'skinny labeling' case: Implications for pharma BD and investors
• HHS Confirms Americans with High-Risk Ebola Exposures Will Have Access to Experimental Therapy MBP-134